70-Gene Breast Cancer Recurrence Test
MammaPrint is the first and currently only breast cancer recurrence test for early-stage breast cancer cleared by the FDA that classifies your breast cancer as having either a Low Risk or High Risk of recurrence. Patients with a Low Risk result are not likely to show a significant benefit from chemotherapy.
MammaPrint examines 70 of the most important genes that predict a cancer’s ability to spread or metastasize. It is the only 70-gene test of its kind that provides a binary (Low or High Risk) result. There are no “intermediate” results. Results from the MammaPrint test, along with your clinical factors (such as tumor size, lymph node involvement and the hormone receptor status of your tumor) help you and your physician make the most informed treatment decisions about your specific type of cancer.
Other genomic tests, such as the Oncotype DX test which only looks at 21 genes, may give you an intermediate result score which can create ambiguity and add little value to you and your physician. Patients have intermediate Oncotype DX scores between 39% – 67%1,2 of the time. MammaPrint, in comparison, provides binary results.
The MammaPrint test is the first and only test to date that has been validated in a randomized, prospective, phase III clinical trial. Recent results from the MINDACT clinical trial provide the highest level of medical evidence (Level 1A), confirming the test’s ability to identify Low Risk patients based on the genomic fingerprint of the tumor who are not likely to show a significant benefit from chemotherapy.
In this clinical trial, 46% of patients identified as high risk for recurrence (according to routine clinical-pathological assessment), and thus likely candidates for adjuvant chemotherapy, were classified as Low Risk (according to the MammaPrint result) and might not require chemotherapy.3
The diagnosis of breast cancer is life changing. Adding certainty with a test that provides Low Risk and High Risk results provides clarity to this traumatic time.
What is the MammaPrint 70-Gene Breast Cancer Recurrence Test?
MammaPrint is a 70-Gene genomic test for early-stage breast cancer patients that will assess the risk of distant metastasis within 5 years. In other words, how likely the cancer is to return and spread to other parts of the body. Results are reported as either a Low Risk or High Risk result.
If a Low Risk result is obtained, there is likely no significant benefit from chemotherapy.
If a High Risk result is obtained, the cancer may recur and there may be a benefit from chemotherapy.
Please consult your physician to determine if the MammaPrint test is right for you. All tests results must be reviewed with your physician in conjunction with other clinical factors before any treatment decisions are made.
Why should my physician order MammaPrint instead of other breast cancer recurrence tests?
Only a licensed medical professional is qualified to determine if the MammaPrint test is right for you. MammaPrint provides easy to understand binary results — High Risk or Low Risk. There are no intermediate results, which can create ambiguity and add little value to you and your physician. Click HERE for more information on MammaPrint’s understandable results Click HERE for more information on MammaPrint’s definitive results.
Additionally, the MammaPrint test is the currently the only breast cancer recurrence test that is supported by Level 1A evidence, which is the highest level of evidence available. This data (from the MINDACT trial) was recently published in New England Journal of Medicine. Click HERE for more information on the MINDACT Study. Click HERE for more information on the MINDACT Study.
MammaPrint is the first and only test to date with U.S. FDA clearance for use in risk assessment for disease recurrence within five years for women of all ages with early-stage breast cancer.
 Carlson, JJ., et al. Breast Cancer Res Treat. (Aug 2013) 141(1): 13–22
 Sparano, JA., et al. N Engl J Med. 2015 Nov 19;373(21):2005-14.
 Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.